Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 12.

Seibold, F; Fournier, N; Beglinger, C; Mottet, C; Pittet, V; Rogler, G (2014). Topical therapy is underused in patients with ulcerative colitis. Journal of Crohn's & colitis, 8(1):56-63.

Hammann, F; Hruz, P; Kullak-Ublick, G A; Vavricka, S R; Beglinger, C; Drewe, J; Gutmann, H (2012). Determination of the Single Nucleotide Polymorphisms C3435 and G2677T in MDR1 and C421A in BCRP in blood samples of patients with inflammatory bowel disease and healthy controls in the swiss population. Metabolomics, 2:104.

Steinert, R E; Gerspach, A C; Gutmann, H; Asarian, L; Drewe, J; Beglinger, C (2011). The functional involvement of gut-expressed sweet taste receptors in glucose-stimulated secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Clinical Nutrition, 30(4):524-532.

Pittet, V; Juillerat, P; Michetti, P; Vader, J P; Burnand, B; Rogler, G; Beglinger, C; Seibold, F; Mottet, C; Felley, C; Gonvers, J J; Froehlich, F; et al; Braegger, C P (2010). Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Alimentary Pharmacology & Therapeutics, 32(8):1007-1016.

Schoepfer, A M; Beglinger, C; Straumann, A; Trummler, M; Vavricka, S R; Bruegger, L E; Seibold, F (2010). Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's Disease (SES-CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology, 105(1):162-169.

Voegtlin, M; Vavricka, S R; Schoepfer, A M; Straumann, A; Voegtlin, J; Rogler, G; Ballabeni, P; Pittet, V; Buser, A; Fried, M; Beglinger, C (2010). Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. Journal of Crohn's and Colitis, 4(6):642-648.

Wojtal, K A; Eloranta, J J; Hruz, P; Gutmann, H; Drewe, J; Beglinger, C; Fried, M; Kullak-Ublick, G A; Vavricka, S R (2009). Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients. Drug Metabolism and Disposition, 37(9):1871-1877.

Michel, B A; Tschumi, U; Woolf, A D; Zeidler, H; Beglinger, C; Dalvit, G; Felder, M; Graf, A; Steurer, J (2009). Chronische muskuloskelettale Schmerzen in der Schweiz: Die Betreuungsqualität aus Sicht der Ärzte und der Patienten. Praxis, 98(17):933-940.

Szucs, T D; Thalmann, C; Michetti, P; Beglinger, C (2009). Cost Analysis of Long-Term Treatment of Patients with Symptomatic Gastroesophageal Reflux Disease (GERD) with Esomeprazole On-Demand Treatment or Esomeprazole Continuous Treatment: An Open, Randomized, Multicenter Study in Switzerland. Value in Health, 12(2):273-281.

Manz, M; Beglinger, C; Vavricka, S R (2009). Fatal invasive pulmonary aspergillosis associated with adalimumab therapy. Gut, 58(1):149.

Beglinger, C; Binek, J; Braegger, C; Michetti, P; Rogler, G; Sauter, B; Seibold, F; Straumann, A (2008). Infliximab-Monotherapie versus Kombinationstherapie mit Immunmodulatoren : Aktuelle Therapieempfehlungen einer Schweizer Expertengruppe. Medical Journal (TMJ), (1):32-34.

Beglinger, C; Thalmann, C; Szucs, T; Michetti, P (2006). Long-term treatment of patients with symptomatic gastroesophageal reflux disease comparing costs and efficacy over 6 months of treatment with Nexium On-Demand Treatment or Nexium continuous treatment. An open, randomised multi-center study. Praxis, 95(13):483-487.

This list was generated on Tue Nov 21 19:23:17 2017 CET.